Combination and head-to-head trials

Some trials give two medicines together. Many more compare one medicine against another. This page sorts the weight-management and diabetes trials in the pipeline by which of the two they are.

75trials with medicines combined

106trials comparing medicines head to head

31combination trials still active

199multi-medicine trials checked

How this was sorted. Every trial here names more than one medicine in the ClinicalTrials.gov registry. For each one, the arm groups were pulled from the registry. The 91 trials whose arms list more than one medicine were read one by one and sorted by hand. The rest were sorted by a plain rule: each medicine sits in its own arm. A medicine that is given on top of another counts as a combination. 12 of the combination trials study CagriSema, which is one product that contains two medicines, cagrilintide and semaglutide. A trial listed here does not mean the combination works or is safe, and it does not mean it is available to buy. The registry does not show doses or results, so this page does not either.

Medicines given together

75 trials. In these trials, at least one arm receives two or more medicines. Many are add-on studies: a new medicine given on top of semaglutide or tirzepatide.

Medicines	Trial	Sponsor	Phase	Status	Start
ALN-2232 + Tirzepatide also known as Mounjaro, Zepbound, LY3298176.	A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALN-2232 as Monotherapy and Co-initiated With Tirzepatide in Adult Participants With Obesity NCT07463846	Alnylam Pharmaceuticals	Phase 1/2	Recruiting	Mar 2026
AMG 598 + Liraglutide also known as Victoza, Saxenda.	A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 598 in Subjects With Obesity NCT03757130	Amgen	Phase 1	Completed	Nov 2018
Apitegromab + Tirzepatide also known as Mounjaro, Zepbound, LY3298176.	A Phase 2 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apitegromab in Overweight and Obese Adult Subjects NCT06445075	Scholar Rock, Inc.	Phase 2	Completed	May 2024
AZD6234 + AZD9550	An Open-label, Single-sequence Multiple Cohort Study to Assess the Effect of Multiple Doses of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on the Pharmacokinetics of Single Doses of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity NCT07013643	AstraZeneca	Phase 1	Active, not recruiting	Jun 2025
AZD9550 + AZD6234	A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Co-administration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight With Co-morbidity (ASCEND) NCT06862791	AstraZeneca	Phase 2	Completed	Feb 2025
BI 1820237 + Liraglutide also known as Victoza, Saxenda.	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Subcutaneous Doses of BI 1820237 Alone (Trial Parts 1+2) or Together With a Low Dose of Liraglutide (Trial Part 3) in Otherwise Healthy Male Subjects With Overweight/Obesity (Single-blind, Randomised, Placebo-controlled, Parallel Group Design) NCT04903509	Boehringer Ingelheim	Phase 1	Completed	Jun 2021
BI 1820237 + Semaglutide + Survodutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus. also known as BI 456906.	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Different Titration Schedules of Subcutaneous Doses of BI 1820237 Alone or Together With Either Semaglutide or BI 456906 in Otherwise Healthy Male and Female Individuals With Obesity/Overweight (Multiple Dose, Single-blind, Randomised, Placebo-controlled, Parallel Group Design) NCT05751226	Boehringer Ingelheim	Phase 1	Completed	Apr 2023
Bimagrumab + Semaglutide also known as BYM338. also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight or Obese Men and Women NCT05616013	Eli Lilly and Company	Phase 2	Completed	Nov 2022
Bimagrumab + Tirzepatide also known as BYM338. also known as Mounjaro, Zepbound, LY3298176.	Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity NCT05933499	Massachusetts General Hospital	Phase 2	Recruiting	Nov 2025
Bimagrumab + Tirzepatide also known as BYM338. also known as Mounjaro, Zepbound, LY3298176.	A Phase 2b Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes NCT06901349	Eli Lilly and Company	Phase 2	Withdrawn	May 2025
Bimagrumab + Tirzepatide also known as BYM338. also known as Mounjaro, Zepbound, LY3298176.	A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight Without Type 2 Diabetes NCT06643728	Eli Lilly and Company	Phase 2	Active, not recruiting	Oct 2024
BIO101 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of 20-hydroxyecdysone (20E) in Reducing the Muscle Strength Loss From the GLP1 Agonist Semaglutide in Combination With Dieting in Obese and Overweight Adult Patients (OBA). NCT07411378	Biophytis	Phase 2	Not yet recruiting	Jul 2026
Cagrilintide + CagriSema	Bioequivalence Study of Cagrilintide B + Placebo Semaglutide I and Cagrilintide D Once Weekly in Participants With Overweight or Obesity NCT07597018	Novo Nordisk A/S	Phase 1	Recruiting	May 2026
Cagrilintide + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Efficacy, Safety and Pharmacokinetics of Cagrilintide s.c. 2.4 mg as Monotherapy and in Combination With Semaglutide s.c. 2.4 mg (CagriSema) Once Weekly for Weight Management in Chidren and Adolescents With Overweight or Obesity NCT07253285	Novo Nordisk A/S	Phase 3	Recruiting	Jan 2026
Cagrilintide + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Long-term Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Placebo in Participants With Obesity NCT06780449	Novo Nordisk A/S	Phase 3	Active, not recruiting	Feb 2025
Cagrilintide + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c.(CagriSema s.c. 1.0 mg/1.0 mg and 1.7 mg/1.7 mg) Once-weekly in Participants With Overweight or Obesity NCT06388187	Novo Nordisk A/S	Phase 3	Completed	Jun 2024
Cagrilintide + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg Once Weekly Versus Placebo in Participants With Type 2 Diabetes as Add on to Once-daily Basal Insulin With or Without Metformin NCT06323161 · Type 2 diabetes only	Novo Nordisk A/S	Phase 3	Completed	Mar 2024
Cagrilintide + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg Once Weekly Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Diet and Exercise NCT06323174 · Type 2 diabetes only	Novo Nordisk A/S	Phase 3	Completed	Mar 2024
Cagrilintide + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4/2.4 mg and 1.0/1.0 mg Once Weekly Versus Semaglutide 2.4 mg and 1.0 mg, Cagrilintide 2.4 mg and Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor NCT06065540 · Type 2 diabetes only	Novo Nordisk A/S	Phase 3	Completed	Sep 2023
Cagrilintide + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-Weekly in Chinese Participants With Overweight or Obesity NCT05996848	Novo Nordisk A/S	Phase 3	Completed	Aug 2023
Cagrilintide + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Efficacy and Safety of Cagrilintide S.C. 2.4 mg in Combination With Semaglutide S.C. 2.4 mg (CagriSema S.C. 2.4 mg/2.4 mg) Once-Weekly in East Asian Participants With Overweight or Obesity NCT05813925	Novo Nordisk A/S	Phase 3	Completed	Apr 2023
Cagrilintide + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 Diabetes NCT05394519	Novo Nordisk A/S	Phase 3	Completed	Feb 2023
Cagrilintide + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity NCT05567796	Novo Nordisk A/S	Phase 3	Active, not recruiting	Nov 2022
Cagrilintide + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Semaglutide 2.4 mg, Cagrilintide 2.4 mg and Placebo in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity NCT06131372	Novo Nordisk A/S	Phase 2	Completed	Apr 2024
Cagrilintide + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Effect of CagriSema, Semaglutide and Cagrilintide on Skeletal Muscle Insulin Sensitivity, Composition and Function NCT07527195	Novo Nordisk A/S	Phase 1	Recruiting	Apr 2026
Cagrilintide + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	The Role of the Amylin Analogue Cagrilintide in Bone Metabolism During Weight Loss in Postmenopausal Women With Obesity NCT07010432	Novo Nordisk A/S	Phase 1	Recruiting	Jun 2025
Cagrilintide + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	An Open-label, One-sequence Cross-over, Single-centre Trial, Investigating the Influence of CagriSema on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Atorvastatin in Participants With Overweight or Obesity NCT06289504	Novo Nordisk A/S	Phase 1	Completed	Feb 2024
Cagrilintide + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	An Investigation of the Effect of Cagrilintide and Semaglutide Combination Treatment(CagriSema) on Energy Intake, Appetite and Gastric Emptying in People With Overweight or Obesity NCT06207877	Novo Nordisk A/S	Phase 1	Completed	Feb 2024
Cagrilintide + Semaglutide + CagriSema also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Investigation of Pharmacokinetics Following Co-administration of Cagrilintide (NNC0174-0833) and Semaglutide Versus Separate Injections in Subjects With Overweight or Obesity NCT04940078	Novo Nordisk A/S	Phase 1	Completed	Jul 2021
Cagrilintide + Semaglutide + Tirzepatide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus. also known as Mounjaro, Zepbound, LY3298176.	Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. Once Weekly Versus Tirzepatide 5 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2 Inhibitor or Both NCT06534411 · Type 2 diabetes only	Novo Nordisk A/S	Phase 3	Completed	Nov 2024
Cagrilintide + Semaglutide + Tirzepatide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus. also known as Mounjaro, Zepbound, LY3298176.	Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. Once Weekly Versus Tirzepatide 15 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor NCT06221969 · Type 2 diabetes only	Novo Nordisk A/S	Phase 3	Completed	Jan 2024
Cagrilintide + Semaglutide + Tirzepatide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus. also known as Mounjaro, Zepbound, LY3298176.	Efficacy and Safety of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly Compared to Tirzepatide 15 mg s.c. Once-weekly in Participants With Obesity NCT06131437	Novo Nordisk A/S	Phase 3	Completed	Nov 2023
CagriSema	Safety And Tolerability of 3 Switch Regimens From Semaglutide 1.0 mg and 2.0 mg to Co-Administered Cagrilintide and Semaglutide (Cagrisema) in Participants With Type 2 Diabetes NCT07817251 · Type 2 diabetes only	Novo Nordisk A/S	Phase 3	Recruiting	Sep 2026
CagriSema	Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. Once Weekly Versus Placebo in Children and Adolescents With Type 2 Diabetes NCT07282613 · Type 2 diabetes only	Novo Nordisk A/S	Phase 3	Recruiting	Aug 2026
CagriSema	A Placebo-controlled Comparability Study to Compare Two Presentations of CagriSema in Participants With Overweight or Obesity NCT07357766	Novo Nordisk A/S	Phase 3	Withdrawn	Jun 2026
CagriSema	Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c. (CagriSema s.c.) Once Weekly for Weight Management and Long-term Weight Maintenance in Participants With Obesity NCT07011667	Novo Nordisk A/S	Phase 3	Active, not recruiting	Jun 2025
CagriSema	A Phase 2 Study to Compare Two Presentations of CagriSema in Participants With Type 2 Diabetes NCT07357740 · Type 2 diabetes only	Novo Nordisk A/S	Phase 2	Withdrawn	Aug 2026
CagriSema	Efficacy and Safety of co Administered Cagrilintide and Semaglutide (CagriSema) Once Weekly Versus Placebo in Participants With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy NCT06797869 · Type 2 diabetes only	Novo Nordisk A/S	Phase 2	Completed	Jan 2025
CagriSema	The Effect of Cagrilintide and Semaglutide Combination Treatment Compared to a Weight-loss Inducing Diet on Energy Metabolism in Persons Living With Obesity: an Open-label Randomised Study NCT07184086	Novo Nordisk A/S	Phase 1	Active, not recruiting	Sep 2025
CagriSema	Comparing the Pharmacokinetics of Cagrilintide and Semaglutide Following Single Subcutaneous Doses of Different CagriSema Presentations, in a Crossover Manner in Adult Participants With Overweight or Obesity NCT06716307	Novo Nordisk A/S	Phase 1	Completed	Dec 2024
CagriSema	An Investigation of the Effect of Cagrilintide and Semaglutide Combination Treatment (CagriSema) on Appetite and Functional Brain Activity in People With Overweight or Obesity NCT06267092	Novo Nordisk A/S	Phase 1	Completed	Feb 2024
CagriSema + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity With or Without Type 2 Diabetes NCT07564414	Novo Nordisk A/S	Phase 3	Recruiting	May 2026
ECC4703 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of ECC4703 as an Adjunct to Semaglutide in Adults With Obesity NCT07505303	Eccogene	Phase 2	Active, not recruiting	Mar 2026
GSK2890457 + Liraglutide also known as Victoza, Saxenda.	A Double-blind [Sponsor Unblinded], Randomized, Placebo-controlled, Staggered-parallel Study to Investigate the Safety, Tolerability, and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes NCT01725126	GlaxoSmithKline	Phase 2	Completed	Feb 2013
HT-6184 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study to Evaluate the Safety, Efficacy and Tolerability of Ofirnoflast (HT-6184) and Semaglutide in Obese or Overweight Participants With Type 2 Diabetes Mellitus (T2DM) NCT07172867	Halia Therapeutics, Inc.	Phase 2	Withdrawn	Jan 2026
JMT206 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Identify the Expanded Access Program, if Any. This is Required Unless the Expanded Access Type is "Individual Patients." A Randomized, Parallel, Double-blind, Placebo-controlled Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of JMT206 Injection Alone or in Combination With Semaglutide in Obese Participants NCT07840729	Shanghai JMT-Bio Inc.	Phase 1	Not yet recruiting	Oct 2026
LUM-201 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of Oral LUM-201 as an Adjunct to Oral Semaglutide for Improving Physical Function in Older Adults With Obesity NCT07754045	Lumos Pharma	Phase 2	Not yet recruiting	Feb 2027
LY3457263 + Tirzepatide also known as Mounjaro, Zepbound, LY3298176.	A Dose-Escalation Treatment, Phase 1, Investigator- and Participant-Blind, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of LY3457263 in Combination With Tirzepatide in Overweight or Obese Participants NCT05582096	Eli Lilly and Company	Phase 1	Completed	Nov 2022
LY3841136 + Tirzepatide also known as Mounjaro, Zepbound, LY3298176.	A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With LY3841136 and Tirzepatide, Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes NCT06603571	Eli Lilly and Company	Phase 2	Completed	Sep 2024
LY3841136 + Tirzepatide also known as Mounjaro, Zepbound, LY3298176.	A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3841136 Monotherapy, and LY3841136 in Combination With Tirzepatide, in Japanese Participants With Obesity or Overweight NCT06297616	Eli Lilly and Company	Phase 1	Completed	Apr 2024
MACUPATIDE + Eloralintide	A Phase 2b, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes NCT07589608	Eli Lilly and Company	Phase 2	Recruiting	May 2026
MACUPATIDE + Eloralintide	A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes NCT07215559	Eli Lilly and Company	Phase 2	Active, not recruiting	Oct 2025
MACUPATIDE + Eloralintide	A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Macupatide Monotherapy, and Macupatide in Combination With Eloralintide, in Japanese Participants With Obesity or Overweight Without Type 2 Diabetes. NCT07765511	Eli Lilly and Company	Phase 1	Not yet recruiting	Oct 2026
Mazdutide + LY3841136 + Tirzepatide + LY3549492 + LY3532226 also known as IBI362, LY3305677. also known as Mounjaro, Zepbound, LY3298176.	A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Interventions for Chronic Weight Management in Adult Participants With Obesity or Overweight NCT06143956	Eli Lilly and Company	Phase 2	Recruiting	Nov 2023
NA-931 + Tirzepatide also known as Mounjaro, Zepbound, LY3298176.	A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Oral NA-931, Alone or in Addition to Open Label Subcutaneous Tirzepatide , to Investigate the Efficacy and Safety in Overweight or Obese Men and Women NCT06732245	Biomed Industries, Inc.	Phase 2	Not yet recruiting	Aug 2026
NNC0114-0006 + Liraglutide also known as Victoza, Saxenda.	A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Multi-centre Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function NCT02443155 · Type 2 diabetes only	Novo Nordisk A/S	Phase 2	Completed	Nov 2015
NNC0165-1562 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	An Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of Multiple Weekly Doses of NNC0165-1562 and Semaglutide in Subjects With Overweight or Obesity NCT03574584	Novo Nordisk A/S	Phase 1	Completed	Jun 2018
NNC0174-0833 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Combination With Semaglutide in Subjects Being Overweight or With Obesity NCT03600480	Novo Nordisk A/S	Phase 1	Completed	Jul 2018
NNC0480 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Investigation of Pharmacokinetic Properties of Subcutaneously co Administered Single Doses of NNC0480-0389 and Semaglutide in Healthy Chinese Male Subjects NCT05498610 · Type 2 diabetes only	Novo Nordisk A/S	Phase 1	Completed	Aug 2022
NNC0480-0389 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Investigation of the Safety and Efficacy of Semaglutide s.c. in Combination With NNC0480-0389 in Participants With Type 2 Diabetes - a Dose Finding Study NCT05144984 · Type 2 diabetes only	Novo Nordisk A/S	Phase 2	Completed	Nov 2021
NNC0480-0389 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Investigation of Safety, Tolerability and Pharmacokinetics of Subcutaneously Co-administered Single Doses of NNC0480-0389 and Semaglutide in Healthy Japanese Male Subjects NCT04878406 · Type 2 diabetes only	Novo Nordisk A/S	Phase 1	Completed	May 2021
NNC0480-0389 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of NNC0480-0389 in Combination With Semaglutide s.c. NCT04259801	Novo Nordisk A/S	Phase 1	Completed	Feb 2020
NNC9204-0530 + Liraglutide also known as Victoza, Saxenda.	A Multiple Dose Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity NCT02870231	Novo Nordisk A/S	Phase 1	Completed	Aug 2016
NNC9204-0530 + Liraglutide also known as Victoza, Saxenda.	A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects. NCT02235961	Novo Nordisk A/S	Phase 1	Completed	Sep 2014
Petrelintide + Enicepatide (CT-388) also known as ZP8396. also known as RO7795081.	A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy and Safety of Petrelintide Co-Administered With RO7795068 in Adults With Obesity or Overweight NCT07589686	Hoffmann-La Roche	Phase 2	Not yet recruiting	Sep 2026
PF-08653945 + PF-08653944	A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE-RANGING, DOSE-FINDING, UMBRELLA STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08653945 AND PF-08653944, ALONE OR IN COMBINATION, IN ADULTS WITH OVERWEIGHT OR OBESITY (SOLIS-1) NCT07575932	Pfizer	Phase 2	Active, not recruiting	May 2026
RN3161 + Tirzepatide also known as Mounjaro, Zepbound, LY3298176.	A Randomized, Double-Blind, Placebo-Controlled Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity NCT07245771	Ikaria Bioscience Pty Ltd	Phase 1/2	Recruiting	Nov 2025
RO7204239 + Tirzepatide also known as Mounjaro, Zepbound, LY3298176.	A Randomized, Double-blind, Placebo-controlled Phase 2 Trial to Assess Efficacy, Safety, and Tolerability of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity NCT06965413	Hoffmann-La Roche	Phase 2	Active, not recruiting	May 2025
Semaglutide + Cagrilintide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Efficacy and Safety of Co-administration of Cagrilintide s.c. 2.4 mg and Semaglutide s.c. 2.4 mg Once Weekly in Subjects With Type 2 Diabetes NCT04982575 · Type 2 diabetes only	Novo Nordisk A/S	Phase 2	Completed	Aug 2021
Semaglutide + Cagrilintide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Effect of CagriSema, Semaglutide and Cagrilintide on Insulin Sensitivity and Pancreatic Endocrine Function in Adults With Type 2 Diabetes NCT06403761 · Type 2 diabetes only	Novo Nordisk A/S	Phase 1	Completed	May 2024
Semaglutide + CS060380 also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Study to Evaluate the Efficacy and Safety of CS060380 Tablets in Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH) and Obesity. NCT07466017	Cascade Pharmaceuticals, Inc	Phase 2	Active, not recruiting	Apr 2026
Semaglutide + NNC0480-0389 also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Study to Investigate the Pharmacokinetics of Semaglutide and NNC0480-0389 When Subcutaneously Administered as a Co-formulation or as Separate Injections in Healthy Participants NCT05046873 · Type 2 diabetes only	Novo Nordisk A/S	Phase 1	Completed	Sep 2021
Tirzepatide + LY3841136 also known as Mounjaro, Zepbound, LY3298176.	A Multiple Dose Combination Study to Evaluate the Safety and Tolerability of Tirzepatide and LY3841136 in Overweight and Obese Participants NCT06345066	Eli Lilly and Company	Phase 1	Completed	Apr 2024
TLC-6740 + Tirzepatide also known as Mounjaro, Zepbound, LY3298176.	A Phase 1/1b Study of Single and Multiple Ascending Doses of TLC 6740 in Healthy Subjects, Including Evaluation of Food Effect and Potential Drug-Drug Interactions, and Preliminary Safety and Efficacy in Subjects With Obesity, With or Without Diabetes NCT05822544	OrsoBio, Inc	Phase 1	Active, not recruiting	Apr 2023
VRB-103 + VRB-101	A Randomized, Double-blind, Placebo-controlled, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight NCT07628127	Verdiva Bio Dev Limited	Phase 1	Recruiting	Jul 2026

Medicines compared head to head

106 trials. Each medicine is in its own arm. These tell you how the medicines compare, not whether they work well together.

Show all 106 head-to-head trials

Medicines	Trial	Sponsor	Phase	Status	Start
AL 150 + AL 100	Ponderal Outcomes After Roux-en-Y Gastric Bypass With Alimentary Limb (AL) of 150cm and Biliopancreatic Limb (BPL) of 100cm vs AL 100cm and BPL 150cm NCT03838276	Hospital General Universitario Elche	Phase 3	Unknown status	Feb 2019
APHD-012 + APHD-002 + APHP-012 + APHP-002	A Phase II Study to Investigate the Efficacy and Safety of Two Different Doses of Twice Daily Distal Jejunal-release Dextrose Beads Formulations (APHD 012 and APHD 002) Combined With a Gel Composition, Compared With Two Different Doses of the Placebo Beads Formulations (APHP 012 and APHP 002) Combined With a Gel Composition in Obese Subjects With Weight Related Comorbidities NCT07008456	Aphaia Pharma US LLC	Phase 2	Recruiting	Sep 2025
APHD-012 + APHD-012P	A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose (Aphaia Technology, AT) in Obese Subjects NCT05385978	Aphaia Pharma US LLC	Phase 2	Active, not recruiting	Nov 2022
AZD5004 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	AZD5004 Phase IIb in T2DM vs placebo and semaglutide NCT06579105 · Type 2 diabetes only	AstraZeneca	Phase 2	Completed	Oct 2024
AZD6234 + AZD9550	A Phase IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD6234, AZD9550, and AZD6234 in Combination With AZD9550 in Chinese Participants Living With Obesity/Overweight NCT07017179	AstraZeneca	Phase 2	Active, not recruiting	May 2025
BENAGLUTIDE + Liraglutide also known as Victoza, Saxenda.	Effects of Benaglutide on Weight and Gut Microbiota in Obese Patients NCT03986008	Xiangya Hospital of Central South University	Phase 3	Unknown status	Dec 2019
BGM0504 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Randomized, Open-Label, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety, and Diabetes Remission of BGM0504 Injection Compared With Semaglutide Injection in Early-Stage Chinese Type 2 Diabetes Mellitus Patients With Obesity and Inadequate Glycemic and Weight Control Despite Diet and Exercise Intervention（BRIGHT-1） NCT07743983	BrightGene Bio-Medical Technology Co., Ltd.	Phase 3	Recruiting	Sep 2026
BGM0504 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	BGM0504 vs semaglutide add-on to metformin in T2D NCT07064486 · Type 2 diabetes only	BrightGene Bio-Medical Technology Co., Ltd.	Phase 3	Active, not recruiting	Jul 2025
BGM0504 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	BGM0504 vs semaglutide add-on to metformin and/or sulfonylureas in T2D NCT06716216 · Type 2 diabetes only	BrightGene Bio-Medical Technology Co., Ltd.	Phase 3	Active, not recruiting	Jan 2025
BGM0504 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	BGM0504 multiple-dose Phase IIa in T2DM vs placebo and semaglutide NCT06974825 · Type 2 diabetes only	BrightGene Bio-Medical Technology Co., Ltd.	Phase 2	Completed	Aug 2023
BGM0504 + Tirzepatide also known as Mounjaro, Zepbound, LY3298176.	A Phase II, Randomized Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BGM0504 Compared to Tirzepatide in Adults Who Have Obesity NCT06911203	BrightGene Bio-Medical Technology Co., Ltd.	Phase 2	Completed	Apr 2025
Bofanglutide + Semaglutide also known as GZR18. also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	BALANCE-DM2: bofanglutide (GZR18) vs semaglutide in Latin American T2D NCT07628985 · Type 2 diabetes only	Carnot Laboratories	Phase 3	Not yet recruiting	Sep 2026
Bofanglutide + Semaglutide also known as GZR18. also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Multicenter, Randomized, Open-Label, Parallel-Group Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide(Wegovy®) in Adult Obese or Overweight Subjects NCT07150975	Gan & Lee Pharmaceuticals.	Phase 3	Recruiting	Sep 2025
Bofanglutide + Semaglutide also known as GZR18. also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	GZR18 vs semaglutide Phase III in Chinese T2D on metformin NCT06778967 · Type 2 diabetes only	Gan & Lee Pharmaceuticals.	Phase 3	Active, not recruiting	Feb 2025
Bofanglutide + Semaglutide also known as GZR18. also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	GZR18 Phase II vs semaglutide in Chinese T2D NCT06256549 · Type 2 diabetes only	Gan and Lee Pharmaceuticals, USA	Phase 2	Unknown status	Aug 2023
Bofanglutide + Tirzepatide also known as GZR18. also known as Mounjaro, Zepbound, LY3298176.	EFFICACY AND SAFETY OF GZR18 INJECTED EVERY 2 WEEKS (Q2W) IN PARTICIPANTS WITHOUT TYPE 2 DIABETES, WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED, TIRZEPATIDE- AND PLACEBO-CONTROLLED STUDY NCT06737042	Gan and Lee Pharmaceuticals, USA	Phase 2	Completed	Feb 2025
COTADUTIDE + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Cotadutide Phase 2b in CKD with T2DM vs placebo and semaglutide NCT04515849 · Type 2 diabetes only	AstraZeneca	Phase 2	Completed	Aug 2020
DWRX5003 + DWC202502 + DWC202503 + DWRX5003P	A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers NCT07539415	Daewoong Pharmaceutical Co. LTD.	Phase 1	Recruiting	May 2026
Ecnoglutide + Liraglutide also known as XW003. also known as Victoza, Saxenda.	A Phase 2, Open-label, Randomised, Dose-Finding Study of XW003, Once-Weekly Human Glucagon-Like Peptide 1 Analogue, Compared With Once-Daily Liraglutide 3 mg in Adult Participants With Obesity NCT05111912	Sciwind Biosciences APAC CO Pty. Ltd.	Phase 2	Completed	Nov 2021
Ecnoglutide + Semaglutide also known as XW003. also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Multicenter, Randomized, Open-label, Treatment Switching Phase II Study to Evaluate the Efficacy and Safety of XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity NCT07073417	Hangzhou Sciwind Biosciences Co., Ltd.	Phase 2	Active, not recruiting	Jul 2025
Enicepatide (CT-388) + Semaglutide also known as RO7795081. also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Once-daily RO7795081, 30 weeks, Phase II in T2DM NCT07112872 · Type 2 diabetes only	Hoffmann-La Roche	Phase 2	Active, not recruiting	Aug 2025
GW869682 + GSK189075	An Exploratory Study to Evaluate Weight Loss, Body Composition Changes, Food Intake and Urine Glucose Excretion in Healthy Obese Subjects Over 8 Weeks of Dosing With GSK189075, GW869682 Versus Placebo NCT00494767	GlaxoSmithKline	Phase 1	Completed	Sep 2006
GZR102 + Bofanglutide also known as GZR18.	GZR102 weekly vs GZR18 biweekly Phase II in T2D on GLP-1 RAs NCT07055386 · Type 2 diabetes only	Gan & Lee Pharmaceuticals.	Phase 2	Active, not recruiting	Aug 2025
GZR102 + Bofanglutide also known as GZR18.	A Randomized, Double-Blind, Crossover Phase I Clinical Study to Evaluate the Safety, Tolerability, PK and PD Profiles of a Single Dose of GZR102 Injection Versus GZR4 Injection and GZR18 Injection Given Separately in Chinese Adult Overweight Subjects NCT06974487	Gan & Lee Pharmaceuticals.	Phase 1	Not yet recruiting	May 2025
HD1916 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	To Evaluate a Multicenter, Randomized, Open, Positive Parallel Controlled Phase III Clinical Trial of Semaglutide Injection (HD1916) in the Treatment of Obesity NCT06604624	CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.	Phase 3	Completed	Sep 2024
HDM1005 + Mazdutide also known as IBI362, LY3305677.	HDM1005 vs mazdutide in T2D on metformin +/- SGLT2 inhibitor NCT07417306 · Type 2 diabetes only	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	Phase 3	Not yet recruiting	Mar 2026
HDM1005 + Tirzepatide also known as Mounjaro, Zepbound, LY3298176.	A Phase 2, Randomized, Open-Label, Controlled Trial to Evaluate the Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes NCT07521631	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	Phase 2	Recruiting	Mar 2026
HDM1702 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Clinical Study Comparing the Efficacy and Safety of Semaglutide Injection and WEGOVY® in Chinese Obese Patients NCT07036172	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	Phase 3	Recruiting	Jan 2025
HR17031 + INS068 + SHR20004	HR17031 vs INS068 vs SHR20004, 26 weeks, T2D on metformin NCT05333835 · Type 2 diabetes only	Jiangsu HengRui Medicine Co., Ltd.	Phase 2	Unknown status	Jul 2022
HRS-4729 + Mazdutide also known as IBI362, LY3305677.	HRS-4729 Phase II in T2D (placebo and mazdutide controlled) NCT07843862 · Type 2 diabetes only	Fujian Shengdi Pharmaceutical Co., Ltd.	Phase 2	Not yet recruiting	Oct 2026
HRS9531 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Multicenter, Randomized, Open-label, Parallel-controlled Phase III Study Comparing the Efficacy and Safety of HRS9531 Injection Versus Semaglutide Injection in Subjects With Obesity NCT07285902	Fujian Shengdi Pharmaceutical Co., Ltd.	Phase 3	Active, not recruiting	Dec 2025
HRS9531 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	HRS9531 vs semaglutide in T2D on metformin +/- SGLT2 inhibitors NCT06649344 · Type 2 diabetes only	Fujian Shengdi Pharmaceutical Co., Ltd.	Phase 3	Completed	Oct 2024
JNJ-64565111 + Liraglutide also known as Victoza, Saxenda.	A Randomized, Double-blind Placebo-controlled and Open-label Active-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Subjects NCT03486392	Janssen Research & Development, LLC	Phase 2	Completed	Mar 2018
LAE103 + LAE102	A Phase I, Randomized, Double-blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LAE103 as Single and Multiple Ascending Doses in Healthy Overweight/Obese Participants, and as Single Dose in Healthy Postmenopausal Women, With an Additional Evaluation of Single Ascending Dose of LAE103 in Combination With LAE102 in Healthy Overweight/Obese Participants NCT07230496	Laekna Limited	Phase 1	Recruiting	Dec 2025
Liraglutide + Naltrexone and bupropion also known as Victoza, Saxenda. also known as Contrave, Mysimba.	Cardiovascular and Metabolic Effects of Drugs for the Treatment of Obesity NCT04575194	National and Kapodistrian University of Athens	Phase 4	Unknown status	Sep 2020
Liraglutide + NNC0090-2746 also known as Victoza, Saxenda.	A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase 2a Study With an Open-Label Active Group to Assess the Efficacy and Safety of Once-Daily NNC0090-2746 in Type 2 Diabetic Patients Inadequately Controlled With Metformin NCT02205528 · Type 2 diabetes only	Novo Nordisk A/S	Phase 2	Completed	Aug 2014
Liraglutide + Orlistat also known as Victoza, Saxenda. also known as Xenical, Alli.	A Real-world Study of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients. NCT07301437	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	Phase 4	Not yet recruiting	May 2026
Liraglutide + Orlistat also known as Victoza, Saxenda. also known as Xenical, Alli.	Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: A 20-week Randomised, Double-blind, Placebo-controlled, Six Armed Parallel Group, Multi-centre, Multinational Trial With an Open Label Orlistat Comparator Arm and With an 84-week Extension Period NCT00422058	Novo Nordisk A/S	Phase 2	Completed	Jan 2007
Liraglutide + Semaglutide also known as Victoza, Saxenda. also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Investigation of the Effect of Fasting Duration and Temporary Withholding of GLP-1 RAs on Retained Gastric Contents in Participants Treated With s.c. Liraglutide, Oral Semaglutide or s.c. Semaglutide NCT07225816	Novo Nordisk A/S	Phase 1	Recruiting	Nov 2025
Maridebart cafraglutide + Semaglutide also known as MariTide, AMG 133. also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Phase 3, Randomized, Open-Label Trial Comparing the Efficacy and Safety of Maridebart Cafraglutide Once Monthly Versus Semaglutide Once Weekly as Add-on Therapy to Metformin With or Without a Sodium-glucose Cotransporter-2 Inhibitor in Participants With Type 2 Diabetes NCT07866066 · Type 2 diabetes only	Amgen	Phase 3	Not yet recruiting	Nov 2026
Mazdutide + Semaglutide also known as IBI362, LY3305677. also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Multicenter, Randomized, Open-label Phase III Study to Compare the Efficacy and Safety of IBI362 and Semaglutide in Chinese Overweight or Obese Subjects With Metabolic Dysfunction-associated Fatty Liver Disease (GLORY-3) NCT06884293	Innovent Biologics (Suzhou) Co. Ltd.	Phase 3	Active, not recruiting	May 2025
Mazdutide + Semaglutide also known as IBI362, LY3305677. also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Multicenter, Randomized, Open-label Phase 3 Study Comparing the Efficacy and Safety of IBI362 Versus Semaglutide in Chinese Participants With Early Type 2 Diabetes and Obesity (DREAMS-3) NCT06184568	Innovent Biologics (Suzhou) Co. Ltd.	Phase 3	Completed	Feb 2024
MEDI0382 + Liraglutide also known as Victoza, Saxenda.	An Exploratory Phase 2, Randomised, Double-blind, Placebo-controlled, and Open-label Active Comparator Study to Evaluate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. NCT03555994	MedImmune LLC	Phase 2	Completed	May 2018
MEDI0382 + Liraglutide also known as Victoza, Saxenda.	A Phase IIb, Randomised, Parallel, Double-Blind Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes Mellitus NCT03235050	AstraZeneca	Phase 2	Completed	Aug 2017
MET233 + MET097	A PHASE 1/2A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MET233 CO-ADMINISTERED WITH MET097 IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT INCLUDING PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS NCT06924320	Pfizer	Phase 1/2	Recruiting	Mar 2025
MWN109 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	MWN109 tablets Phase II in T2DM vs placebo and oral semaglutide NCT07801820 · Type 2 diabetes only	Shanghai Minwei Biotechnology Co., Ltd	Phase 2	Recruiting	Jun 2026
NNC0148-0287SEMA + Semaglutide + NNC0148-0287 also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Trial to Investigate Single Dose Pharmacokinetics of NNC0148-0287sema in a Fixed Ratio Compared With Insulin 287 and Semaglutide Given Separately in Subjects With Type 2 Diabetes NCT03789578 · Type 2 diabetes only	Novo Nordisk A/S	Phase 1	Completed	Jan 2019
NNC0174-0833 + Liraglutide also known as Victoza, Saxenda.	Investigation of Safety and Efficacy of NNC0174-0833 for Weight Management - a Dose Finding Trial. NCT03856047	Novo Nordisk A/S	Phase 2	Completed	Mar 2019
NNC0174-1213 + Cagrilintide	A Randomized, Placebo Controlled and Double-blinded Study Assessing the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Administrations of NNC0174 1213 in Male Participants With Overweight or Obesity. NCT06719011	Novo Nordisk A/S	Phase 1	Completed	Dec 2024
NNC0487-0111 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Efficacy and Safety of NNC0487-0111 s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 8) NCT07400107	Novo Nordisk A/S	Phase 3	Not yet recruiting	May 2026
NNC0519-0130 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Efficacy, Safety and Pharmacokinetics of NNC0519-0130 Once Weekly s.c. Versussemaglutide 1.0 mg and Placebo in People With Chronic Kidney Disease, With or Without Type 2 Diabetes, and With Overweight or Obesity: a Proof-of-concept and Dose-finding Study NCT06717698	Novo Nordisk A/S	Phase 2	Recruiting	Dec 2024
NNC0519-0130 + Tirzepatide also known as Mounjaro, Zepbound, LY3298176.	Investigation of the Safety and Efficacy of Once Weekly NNC0519-0130 in Participants With Overweight or Obesity - a Dose Finding Study NCT06326060	Novo Nordisk A/S	Phase 2	Completed	Mar 2024
NNC0519-0130 + TRIZEPATIDE	Investigation of the Safety and Efficacy of Once Weekly NNC0519-0130 in Participants With Type 2 Diabetes - a Dose Finding Study NCT06326047 · Type 2 diabetes only	Novo Nordisk A/S	Phase 2	Completed	Mar 2024
NNC0662-0419 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Evaluation of Different Dose Escalation Regimens for NNC0662-0419 in Participants With Obesity NCT07639021	Novo Nordisk A/S	Phase 2	Active, not recruiting	Jun 2026
NNC0662-0419 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Efficacy and Safety of Once-weekly Subcutaneous NNC0662-0419 in Participants With Type 2 Diabetes - a Dose-finding Study NCT07415954 · Type 2 diabetes only	Novo Nordisk A/S	Phase 2	Recruiting	Apr 2026
NNC0721-8060 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0721-8060 in Healthy Adult Participants Living With Overweight or Obesity NCT07767175	Novo Nordisk A/S	Phase 1	Recruiting	Aug 2026
Orforglipron + IBI3042 also known as Foundayo, LY3502970.	A Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of Single-Dose IBI3042 in Healthy Participants and Multiple-Dose IBI3042 in Overweight or Obese Participants NCT07793019	Innovent Biologics (Suzhou) Co. Ltd.	Phase 1	Recruiting	Sep 2026
Orforglipron + Semaglutide also known as Foundayo, LY3502970. also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-3) NCT06045221 · Type 2 diabetes only	Eli Lilly and Company	Phase 3	Completed	Sep 2023
PF-07081532 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE RANGING, DOSE FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-07081532, AND OPEN LABEL ORAL SEMAGLUTIDE, IN ADULTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INADEQUATELY CONTROLLED ON METFORMIN, AND SEPARATELY PF-07081532 COMPARED TO MATCHING PLACEBO IN ADULTS WITH OBESITY BUT WITHOUT T2DM NCT05579977	Pfizer	Phase 2	Terminated	Oct 2022
PF-07081532 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE EFFECT OF TWO STEADY-STATE DOSE LEVELS OF PF-07081532 ON THE PHARMACOKINETICS OF SINGLE-DOSE MIDAZOLAM, OMEPRAZOLE AND AN ORAL CONTRACEPTIVE, AND THE EFFECT OF STEADY-STATE SEMAGLUTIDE ON THE PHARMACOKINETICS OF SINGLE-DOSE MIDAZOLAM, IN OBESE ADULT FEMALE PARTICIPANTS NCT05671653	Pfizer	Phase 1	Terminated	Jan 2023
PG-102 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	PG-102 24-week Phase 2 vs placebo and open-label semaglutide in T2DM NCT07187856 · Type 2 diabetes only	ProGen. Co., Ltd.	Phase 2	Not yet recruiting	Jan 2026
Phentermine + Orforglipron also known as Adipex-P, Lomaira. also known as Foundayo, LY3502970.	Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1-based Therapy Discontinuation NCT07729332	Massachusetts General Hospital	Phase 4	Not yet recruiting	Nov 2026
RAY1225 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	RAY1225 vs semaglutide add-on to oral antidiabetic drugs in T2D NCT07139548 · Type 2 diabetes only	Guangdong Raynovent Biotech Co., Ltd	Phase 3	Not yet recruiting	Aug 2025
Retatrutide + Semaglutide also known as LY3437943. also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Phase 3, Randomized, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) NCT06260722 · Type 2 diabetes only	Eli Lilly and Company	Phase 3	Active, not recruiting	Feb 2024
Retatrutide + Semaglutide also known as LY3437943. also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Phase 1, Investigator- and Participant-Blinded Study to Evaluate the Effect of Retatrutide on α- and β- Cell Function and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus NCT06982859 · Type 2 diabetes only	Eli Lilly and Company	Phase 1	Active, not recruiting	Jun 2025
Retatrutide + Tirzepatide also known as LY3437943. also known as Mounjaro, Zepbound, LY3298176.	A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity NCT06662383	Eli Lilly and Company	Phase 3	Active, not recruiting	Nov 2024
RIBUPATIDE + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Phase 3, Randomized, Active- and Placebo-Controlled, Partially-Blinded Study to Compare the Efficacy and Safety of KAI-9531 Administered Once Weekly Versus Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes NCT07284979	Kailera	Phase 3	Active, not recruiting	Dec 2025
RT-114 + PG-102	A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of RT-114 in Healthy Volunteers NCT06891287	RANI Therapeutics	Phase 1	Recruiting	Dec 2025
Semaglutide + BGM0504 also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	An Investigator-Initiated, Randomized, Open-Label, Active-Controlled Study Comparing the Effects of BGM0504 Injection Versus Semaglutide Injection on Insulin Sensitivity and Body Weight in Obese Subjects NCT07836140	Second Affiliated Hospital of Soochow University	Phase 2	Completed	Apr 2024
Semaglutide + Liraglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus. also known as Victoza, Saxenda.	Effect and Safety of Subcutaneous Semaglutide 2.4 mg Once Weekly Compared to Liraglutide 3.0 mg Once Daily on Weight Management in Subjects With Overweight or Obesity NCT04074161	Novo Nordisk A/S	Phase 3	Completed	Sep 2019
Semaglutide + Liraglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus. also known as Victoza, Saxenda.	Efficacy and Safety of Semaglutide 1.0 mg Once-weekly Versus Liraglutide 1.2 mg Once-daily as add-on to 1-3 Oral Anti-diabetic Drugs (OADs) in Subjects With Type 2 Diabetes NCT03191396 · Type 2 diabetes only	Novo Nordisk A/S	Phase 3	Completed	Jun 2017
Semaglutide + Liraglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus. also known as Victoza, Saxenda.	Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes NCT03018028 · Type 2 diabetes only	Novo Nordisk A/S	Phase 3	Completed	Jan 2017
Semaglutide + Liraglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus. also known as Victoza, Saxenda.	Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus NCT02863419 · Type 2 diabetes only	Novo Nordisk A/S	Phase 3	Completed	Aug 2016
Semaglutide + Liraglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus. also known as Victoza, Saxenda.	Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus NCT02453711	Novo Nordisk A/S	Phase 2	Completed	Oct 2015
Semaglutide + Liraglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus. also known as Victoza, Saxenda.	Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes NCT02461589 · Type 2 diabetes only	Novo Nordisk A/S	Phase 2	Completed	Sep 2015
Semaglutide + Liraglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus. also known as Victoza, Saxenda.	Investigation of Safety and Efficacy of Five Doses of Semaglutide Versus Placebo and Open-label Liraglutide, as Add on Therapy, in Subjects Diagnosed With Type 2 Diabetes Currently Treated With Metformin or Controlled With Diet and Exercise A 12 Week Multi-centre, Multi National, Double-blind, Placebo-controlled, Randomised, Nine Armed Parallel Group, Dose Finding Trial NCT00696657 · Type 2 diabetes only	Novo Nordisk A/S	Phase 2	Completed	Jun 2008
Semaglutide + Orlistat + Phentermine and topiramate + Naltrexone and bupropion + Liraglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus. also known as Xenical, Alli. also known as Qsymia. also known as Contrave, Mysimba. also known as Victoza, Saxenda.	Effectiveness of Semaglutide 2.4 mg vs. Commercially Available Medications for Chronic Weight Management in Participants With Obesity in a Multi-employer Setting in The US - a Pragmatic Clinical Study NCT05579249	Novo Nordisk A/S	Phase 4	Completed	Jan 2023
Semaglutide + Phentermine and topiramate + Naltrexone and bupropion also known as Ozempic, Wegovy, Wegovy HD, Rybelsus. also known as Qsymia. also known as Contrave, Mysimba.	Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder - OBOE-Mayo NCT07213466	Mayo Clinic	Phase 4	Recruiting	Jan 2026
Semaglutide + Tirzepatide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus. also known as Mounjaro, Zepbound, LY3298176.	A Randomized, Placebo-Controlled Trial of the Effects of Long-Acting GLP-1 or Dual Incretin (GLP-1 and GIP) Modulation on Gastric Motor Functions NCT06801015	Mayo Clinic	Phase 4	Active, not recruiting	Oct 2025
Semaglutide + Tirzepatide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus. also known as Mounjaro, Zepbound, LY3298176.	Efficacy and Safety of Bariatric Surgery, Semaglutide Once Weekly, and Tirzepatide Once Weekly in Patients With Obesity NCT06803888	Ali Aminian	Phase 4	Active, not recruiting	Jan 2025
Semaglutide + Tirzepatide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus. also known as Mounjaro, Zepbound, LY3298176.	A PHASE 3 STUDY TO EVALUATE THE SWITCH TO MONTHLY BEROBENATIDE FOR MAINTAINING WEIGHT IN ADULTS WHO ARE ON WEEKLY SEMAGLUTIDE OR TIRZEPATIDE (VESPER-SWITCH) NCT07845500	Pfizer	Phase 3	Recruiting	Sep 2026
Semaglutide + Tirzepatide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus. also known as Mounjaro, Zepbound, LY3298176.	Evaluating the Efficacy of Various Weekly GLP1receptor Agonist Among Obese Individuals Without Diabetes NCT07834398	Zagazig University	Phase 3	Completed	Nov 2025
Semaglutide + Tirzepatide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus. also known as Mounjaro, Zepbound, LY3298176.	GLP-RA , DIABETIC , NON-DIABETIC , BMI ,TYG-index , HDL-C NCT07820111	Zagazig University	Phase 3	Completed	Oct 2025
Semaglutide + Tirzepatide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus. also known as Mounjaro, Zepbound, LY3298176.	Male Fertility Preservation: Efficacy Evaluation of GLP-1Receptor Agonist Therapy for Infertility in Obese Males - A Multicenter Clinical Randomized Controlled Trial NCT07179120	First Affiliated Hospital of Wenzhou Medical University	Phase 2	Not yet recruiting	May 2026
Semaglutide + Tirzepatide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus. also known as Mounjaro, Zepbound, LY3298176.	A Phase 1B, Randomized, Open-label, Active-controlled, Parallel, Multiple-dose Study Comparing the Safety, Pharmacokinetics and Efficacy of Dehydratech Cannabidiol and Glucagon-like Peptide 1 Agonists Alone and in Combination, in Overweight or Obese, pre-and Type 2 Diabetic Participants. NCT06648031	Lexaria Bioscience Corp.	Phase 1	Completed	Dec 2024
Survodutide + Semaglutide also known as BI 456906. also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	BI 456906 dose-finding vs placebo and semaglutide in T2D, 16 weeks NCT04153929 · Type 2 diabetes only	Boehringer Ingelheim	Phase 2	Completed	Apr 2020
Survodutide + Semaglutide also known as BI 456906. also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	An Active-comparator-controlled, Open-label, Parallel Group Study to Evaluate the Effect of Survodutide on Energy Expenditure and Fatty Acid Oxidation in Subjects With Obesity NCT06745284	Boehringer Ingelheim	Phase 1	Active, not recruiting	Mar 2025
Survodutide + Semaglutide also known as BI 456906. also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Open-label, Randomised, 4 Parallel-group, Phase I Clinical Trial to Investigate BI 456906 Occupancy of Glucagon Receptors in Liver and Glucagon-like Peptide 1 Receptors in Pancreas in Comparison With Semaglutide After Administration of Radiolabeled Tracer in Male and Female Subjects With Obesity Using PET and MRI NCT05202353	Boehringer Ingelheim	Phase 1	Active, not recruiting	Nov 2024
SYH9017 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic of SYH9017 in Chinese Participants With Overweight and Obesity Following Single and Multiple Doses NCT06830343	CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.	Phase 1	Recruiting	Feb 2025
TCI378 + TCI507	The Evaluation of TCI378 and TCI507 Probiotics on Weight-lowering Efficacy in Adults NCT04910620	National Taiwan University Hospital	Phase 4	Unknown status	Jun 2021
Tirzepatide + Eloralintide also known as Mounjaro, Zepbound, LY3298176.	A Phase 3 Study to Investigate the Efficacy and Safety of LY900043 in Adult Participants With Obesity Without Type 2 Diabetes NCT07881432	Eli Lilly and Company	Phase 3	Not yet recruiting	Dec 2026
Tirzepatide + Eloralintide also known as Mounjaro, Zepbound, LY3298176.	A Phase 3 Study to Investigate the Efficacy and Safety of LY900043 in Adult Participants With Obesity or Overweight and Type 2 Diabetes NCT07881458	Eli Lilly and Company	Phase 3	Not yet recruiting	Nov 2026
Tirzepatide + Eloralintide also known as Mounjaro, Zepbound, LY3298176.	A Phase 1, Open-Label, Single and Multiple Dose Study to Investigate the Safety, Tolerability, and Relative Bioavailability of Single and Multiple Weekly Subcutaneous Doses of Eloralintide, and Single and Multiple Weekly Subcutaneous Doses of Eloralintide With Tirzepatide in Participants With Overweight or Obesity NCT06916065	Eli Lilly and Company	Phase 1	Completed	Apr 2025
Tirzepatide + Liraglutide also known as Mounjaro, Zepbound, LY3298176. also known as Victoza, Saxenda.	Effect of Tirzepatide on Energy Intake and Appetite-and Reward-Related Brain Areas in Overweight/Obese Subjects: A Placebo-Controlled 6-Week Study With Functional MRI NCT04311411	Eli Lilly and Company	Phase 1	Completed	Aug 2020
Tirzepatide + Mazdutide also known as Mounjaro, Zepbound, LY3298176. also known as IBI362, LY3305677.	Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg Administered Multiple Times in Chinese Patients With Moderate to Severe Obesity NCT07000955	Innovent Biologics (Suzhou) Co. Ltd.	Phase 1/2	Active, not recruiting	Jun 2025
Tirzepatide + Naltrexone and bupropion + Phentermine and topiramate + Semaglutide also known as Mounjaro, Zepbound, LY3298176. also known as Contrave, Mysimba. also known as Qsymia. also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial) NCT06854614	The Cleveland Clinic	Phase 4	Active, not recruiting	Mar 2025
Tirzepatide + Semaglutide also known as Mounjaro, Zepbound, LY3298176. also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide in Adults Who Have Obesity or Overweight With Weight Related Comorbidities NCT05822830	Eli Lilly and Company	Phase 3	Completed	Apr 2023
Tirzepatide + Semaglutide also known as Mounjaro, Zepbound, LY3298176. also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes NCT03987919 · Type 2 diabetes only	Eli Lilly and Company	Phase 3	Completed	Jul 2019
Tirzepatide + Semaglutide also known as Mounjaro, Zepbound, LY3298176. also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	The Effect of Tirzepatide on α and β Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus NCT03951753 · Type 2 diabetes only	Eli Lilly and Company	Phase 1	Completed	Jun 2019
UBT251 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	UBT251 vs semaglutide Phase III in T2D on metformin (UNIGUIDE-2) NCT07653477 · Type 2 diabetes only	The United Bio-Technology (Hengqin) Co., Ltd.	Phase 3	Recruiting	Sep 2026
UBT251 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Efficacy and Safety of Once-weekly Subcutaneous UBT251 in Participants With Type 2 Diabetes - a Dose-finding Study NCT07668388 · Type 2 diabetes only	Novo Nordisk A/S	Phase 2	Recruiting	Jun 2026
VI-0521 + Phentermine also known as Adipex-P, Lomaira.	A Multicenter, Randomized, Double-Blind Study to Compare the Effects of VI-0521,Phentermine, and Placebo on Ambulatory Blood Pressure in Overweight or Obese Subjects NCT05215418	VIVUS LLC	Phase 4	Completed	Jan 2022
VI-0521 + Phentermine also known as Adipex-P, Lomaira.	A Phase III, Randomized, Double-Blind, Parallel-Design Study Comparing Multiple Doses of VI-0521 to Placebo and Their Single-Agent Phentermine and Topiramate Constituents for the Treatment of Obesity in Adults NCT00563368	VIVUS LLC	Phase 3	Completed	Dec 2007
VTX3232 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTX3232 Alone or in Combination With Semaglutide in Participants With Obesity NCT06771115	Zomagen Biosciences Ltd.	Phase 2	Completed	Jan 2025
VX-201 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Randomized, Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Epi/Intra-dermally Administered Semaglutide (VX-201) Compared to Subcutaneous Administration in Healthy Overweight and Obese Participants: Single and Multiple Dose Assessment NCT07673900	Terrestrial Bio, Inc.	Phase 1	Recruiting	Jun 2026
ZOVAGLUTIDE + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Multicenter, Randomized, Active-Controlled, Open-Label Phase IIb Study Evaluating Safety and Tolerability of Switching to Zovaglutide Injection After Titration to 2.4 mg Semaglutide Injection (Wegovy®) in Adults With Obesity (HORIZON-SWITCH-SZ) NCT07812597	Beijing QL Biopharmaceutical Co.,Ltd	Phase 2	Not yet recruiting	Oct 2026

Other designs

These trials name more than one medicine but do not fit either group above.

5 trials test one medicine. The other names are placebo, a delivery device or a diet.
6 trials are drug-interaction or crossover studies, where people receive the medicines in a set order to see how they affect each other in the body.
7 trials have arm details the registry does not make clear. Open the registry record to see their design.

Show these 18 trials

Medicines	Trial	Sponsor	Phase	Status	Start
ATL-962 + Orlistat also known as Xenical, Alli.	Multicentre Double Blind Placebo Controlled Parallel Group Dose Ranging Study of ATL-962 to Assess Weight Loss, Safety and Tolerability in Obese Patients With Type II Diabetes Being Treated With Metformin, in Comparison With Orlistat NCT00156897	Alizyme	Phase 2	Completed	Dec 2004
HRS-1780 + HR20033 + HRS-7535	PK interaction of HRS-1780, henagliflozin, metformin and HRS-7535 in healthy subjects NCT06495931 · Type 2 diabetes only	Shandong Suncadia Medicine Co., Ltd.	Phase 1	Completed	Jul 2024
HRS-4729 + HRS9531	A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Subcutaneous Injections of HRS-4729 Injection in Healthy Subjects NCT06762600	Fujian Shengdi Pharmaceutical Co., Ltd.	Phase 1	Completed	Jan 2025
Liraglutide + Orlistat also known as Victoza, Saxenda. also known as Xenical, Alli.	Clinical Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism-associated Fatty Liver Disease (MAFLD) NCT06501326	Affiliated Hospital of Nantong University	Phase 4	Unknown status	Nov 2023
Liraglutide + Phentermine also known as Victoza, Saxenda. also known as Adipex-P, Lomaira.	Combining Lifestyle Modification and Liraglutide to Improve Weight Loss and Health Outcomes NCT02911818	University of Pennsylvania	Phase 4	Completed	Sep 2016
NG101 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Proof-of-Concept, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of Oral NG101 in the Treatment of Side Effects in Healthy Adult Participants Administered a Single Subcutaneous Dose of a Glucagon-Like Peptide 1 Agonist NCT06500429	Neurogastrx, Inc.	Phase 2	Completed	Jun 2024
NNC0165-1875 + Semaglutide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0165-1875 as Monotherapy and in Combination With Semaglutide in Subjects With Overweight or Obesity NCT03707990	Novo Nordisk A/S	Phase 1	Completed	Oct 2018
PF-07976016 + Danuglipron also known as PF-06882961.	A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE PHARMACOKINETIC INTERACTIONS BETWEEN PF-07976016 AND PF-06882961 IN OTHERWISE HEALTHY ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY NCT06910839	Pfizer	Phase 1	Terminated	Mar 2025
Phentermine and topiramate + Liraglutide + Naltrexone and bupropion + Phentermine also known as Qsymia. also known as Victoza, Saxenda. also known as Contrave, Mysimba. also known as Adipex-P, Lomaira.	Individualized Pharmacological Approach to Obesity Management: A Randomized Clinical Trial NCT03374956	Mayo Clinic	Phase 3	Completed	Dec 2017
Phentermine and topiramate + Naltrexone and bupropion + Liraglutide + Orlistat also known as Qsymia. also known as Contrave, Mysimba. also known as Victoza, Saxenda. also known as Xenical, Alli.	An ObEsity-centric Approach With and Without Anti-obesity Medications ComPared to the Usual-care ApprOach to Management of Patients With Obesity and Type 2 Diabetes in an Employer Setting: A Pragmatic Randomized Controlled Trial NCT04531176	The Cleveland Clinic	Phase 4	Terminated	Sep 2020
Semaglutide + DV3372 + PDS290 also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Trial to Compare Pharmacokinetic Properties of Semaglutide Following Subcutaneous Administration of Semaglutide 1 mg by the DV3372 Device and by the PDS290 Semaglutide Pen-injector NCT03611322 · Type 2 diabetes only	Novo Nordisk A/S	Phase 1	Completed	Aug 2018
Semaglutide + DV3372 + PDS290 also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Trial to Demonstrate Bioequivalence Between Semaglutide Formulations for the DV3372 Device and the Formulation for the PDS290 Semaglutide Pen-injector NCT03598621 · Type 2 diabetes only	Novo Nordisk A/S	Phase 1	Completed	Jul 2018
Semaglutide + NNC0385-0434 also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	A Study Investigating Pharmacokinetic Properties When Dosing Different Formulations of Oral Peptide Therapeutics in Healthy Male Participants NCT05129891 · Type 2 diabetes only	Novo Nordisk A/S	Phase 1	Completed	Nov 2021
Semaglutide + NNC0480-0389 also known as Ozempic, Wegovy, Wegovy HD, Rybelsus.	Investigation of the Effect of Subcutaneously Co-administered Semaglutide and NNC0480-0389 on Pharmacokinetics of an Oral Combination Contraceptive (Ethinylestradiol and Levonorgestrel) in Healthy Postmenopausal Females NCT05153564 · Type 2 diabetes only	Novo Nordisk A/S	Phase 1	Completed	Dec 2021
Semaglutide + Tirzepatide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus. also known as Mounjaro, Zepbound, LY3298176.	Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women NCT07057310	Mayo Clinic	Phase 4	Enrolling by invitation	May 2025
Semaglutide + Tirzepatide also known as Ozempic, Wegovy, Wegovy HD, Rybelsus. also known as Mounjaro, Zepbound, LY3298176.	Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide - in Adolescents (the PRESSURE Trial) NCT06575738	University of Colorado, Denver	Phase 1	Recruiting	Oct 2024
Survodutide + BI 1820237 also known as BI 456906.	A Single-dose, Randomized, Placebo-controlled Phase I Study on the Effects of a Subcutaneous Dose of BI 1820237 and BI 456906, and Combination Thereof on Functional MRI Measurements in Otherwise Healthy Male and Female Individuals With Obesity/Overweight (Single-blind, Cross-over Design) NCT06352424	Boehringer Ingelheim	Phase 1	Completed	Apr 2024
T2026 + Ecnoglutide also known as XW003.	A Phase 1, Randomised, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ecnoglutide Tablet in Healthy Adult Participants NCT05184322	Sciwind Biosciences APAC CO Pty. Ltd.	Phase 1	Completed	Apr 2022

Source: ClinicalTrials.gov, run by the US National Library of Medicine. Back to the full pipeline tracker.